GnomeDX Launches Personalized Medicine Services to Improve Patient Outcomes and Reduce Health Care Costs

Business Wire

COLUMBUS, Ohio--(BUSINESS WIRE)-- Gnome Diagnostics, LLC (GnomeDX), a CLIA-certified personalized medicine company, announced the launch of its pharmacogenomic testing services - healthcare's newest forefront of personalized medicine for patients.

Adverse drug reactions are the 4th leading cause of death in the United States ahead of stroke, Alzheimer’s disease, and diabetes, and are estimated to account for $136 billion dollars in health care costs annually. Today, the FDA includes pharmacogenetic information on 137 prescription labels, such as Warfarin and Plavix, detailing the potential risks to taking a drug based on an individual’s genetics.

A simple cotton swab of the inner cheek can be the difference between a patient's best opportunity for drug efficacy or the unnecessary trial and error of taking a drug that may lead to an adverse drug response. GnomeDX’s test results are presented in a clear and concise report that helps clinicians choose the right drug at the right dose for the right person.

“For the first time, the cost of genomic testing is low enough to become a routine medical test to help identify which drugs are best for patients. Often times patients will either not respond to certain drugs or may experience life threatening side effects many of which can often be prevented by a simple test. In addition, utilizing these tests will not only dramatically improve patient outcomes, but also will save an enormous amount of money,” says founder Adel Mikhail, Ph.D.

Testing services are immediately available for clinicians to order, and are often covered by Medicare and insurance. Tests range from cardiology to mental health to pain management. For more information on how pharmacogenetics can benefit patients, contact GnomeDX at gnomedx.com.

About Gnome Diagnostics: GnomeDX’s genetic tests help physicians to prescribe the safest and most effective dose based on an individual's unique genetic profile. In addition, the GnomeDX panel tests can screen for inherited cardiovascular disease risk, promoting early detection and prevention. GnomeDX’s goal is to improve the treatment outcomes for patients, minimize risk and side effects from prescription drugs, and help reduce the overall cost of healthcare.